Ecmo Clinical Trials
Here are the 6 most popular medical studies for ecmo
Ventilation Strategies for ARDS
This trial will study the best way to ventilate patients with severe ARDS who are supported by Veno-Venous ECMO. The two phases will study the impact of tidal ventilation and the level of Positive End-Expiratory Pressure on VILI, with the goal of reducing lung injury.
ECMO Lung Transplantation vs Off-pump Lung Transplantation for Lung Transplant
This trial is comparing two techniques for performing a bilateral lung transplant: off-pump vs venoarterial ECMO. The goal is to determine which has lower rates of primary graft dysfunction.
Ecmo Clinical Trials With No Placebo
View 21 ecmo medical studies that do not have a placebo group.
Ventilation Strategies for Acute Respiratory Distress Syndrome
This trial will study how different ventilator strategies impact the treatment of patients with acute respiratory failure on ECMO. Patients will be put into two groups and assigned different ventilator protocols to compare the effects.
Frequently Asked Questions
Introduction to ecmo
What are the top hospitals conducting ecmo research?
In the realm of cutting-edge healthcare, Extracorporeal Membrane Oxygenation (ECMO) plays a crucial role in saving lives. ECMO is a life-support technique that provides temporary cardiovascular and respiratory support to patients with severe heart or lung failure. When it comes to conducting innovative clinical trials in this field, several hospitals across North America have emerged as pioneers.
Toronto General Hospital, located in the vibrant city of Toronto, leads the charge with two ongoing ECMO trials. With its advanced facilities and expertise, this renowned institution is at the forefront of exploring new possibilities for enhancing patient outcomes using ECMO technology.
Meanwhile, Johns Hopkins All Children's Hospital situated in Saint Petersburg focuses on providing exceptional pediatric care. Despite having only one active ECMO trial currently underway, their dedication to research and innovation ensures that children facing critical cardiac or respiratory challenges receive state-of-the-art treatment options.
In Atlanta, Children's Healthcare of Atlanta - Emory stands out as a leading center for pediatric healthcare services. This esteemed hospital is also committed to advancing knowledge in the field of ECMO through their involvement in an active clinical trial.
Further west lies Iowa City where University of Iowa Health Care employs its resources towards improving patient outcomes utilizing ECMO therapy. They too are engaged in an ongoing clinical trial focusing on refining techniques and optimizing results for individuals experiencing severe heart or lung dysfunction.
Finally, Morgan Stanley Children's Hospital of New Yorks Iowa City where University of Iowa Health Care employs its resources towards improving patient outcomes utilizing ECMO therapy. They too are engaged in an ongoing clinical trial focusing on refining techniques and optimizing results for individuals experiencing severe heart or lung dysfunction.
Finally, Morgan Stanley Children's Hospital of New York Presbyterian contributes to these efforts by actively participating in an ECMO trial aimed at pushing boundaries and revolutionizing care methods for critically ill pediatric patients residing within bustling New York City.
Although these hospitals may not yet have conducted any previous all-time ECMO trials themselves according to available data records; however they do not shy away from embracing novel approaches by initiating various current experiments which aim at broadening our understanding regarding application and effectiveness of ecmo therapy hence ensuring better prospects inclusive recovery; thus exemplifying how dedicated professionals across different locations collaborate tirelessly to push the boundaries of medical knowledge and care. Through their collective efforts, they pave the way for future breakthroughs in ECMO technology that will undoubtedly save lives and improve patient outcomes around the world.
Which are the best cities for ecmo clinical trials?
When it comes to ECMO clinical trials, several cities are at the forefront of groundbreaking research. Toronto, Ontario leads the way with 9 active trials, focusing on Venovenous ECMO and other innovative approaches. Following closely behind is New York, New York, with 4 ongoing studies exploring lower platelet transfusion strategies and Cefiderocol among others. Durham, North Carolina also plays a significant role in ECMO research with 3 active trials investigating lower platelet transfusion strategies and Ultra-Lung Protective Ventilation. Although Atlanta, Georgia and Boston, Massachusetts is New York, New York, with 4 ongoing studies exploring lower platelet transfusion strategies and Cefiderocol among others. Durham, North Carolina also plays a significant role in ECMO research with 3 active trials investigating lower platelet transfusion strategies and Ultra-Lung Protective Ventilation. Although Atlanta, Georgia and Boston, Massachusetts have fewer active trials in this field (2 each), they still contribute valuable insights through studies on various treatment strategies. These cities serve as hubs for pioneering ECMO clinical trials that shape the future of critical care medicine.
Which are the top treatments for ecmo being explored in clinical trials?
ECMO, or extracorporeal membrane oxygenation, is a life-saving therapy used to support patients with severe respiratory or cardiac failure. Ongoing clinical trials are exploring various treatments to enhance the effectiveness and outcomes of ECMO. The top treatments being investigated include:
- Inhaled nitric oxide: A gas that helps improve blood flow and oxygenation.
- Extracellular vesicles: Small particles released by cells that have potential therapeutic effects.
- Mesenchymal stem cells: Cells capable of modulating inflammation and promoting tissue repair.
These innovative approaches aim to advance the field of ECMO and offer new possibilities for critically ill patients in need of this treatment.
What are the most recent clinical trials for ecmo?
Exciting advancements have emerged in the field of ECMO (extracorporeal membrane oxygenation), with recent clinical trials offering promise and potential for improved outcomes. One such trial focuses on subcutaneous heparin administration, exploring its efficacy as an anticoagulant during ECMO therapy. This Phase 2/3 study aims to provide valuable insights into optimizing treatment strategies and enhancing patient safety. Additionally, a Phase 1 trial investigates the use of Cefiderocol, assessing its potential benefits in managing infections associated with ECMO support. These cutting-edge studies highlight the ongoing efforts to refine ECMO protocols and broaden therapeutic options for patients requiring this life-saving intervention.
What ecmo clinical trials were recently completed?
Recently completed clinical trials in the field of ECMO (Extracorporeal Membrane Oxygenation) have made significant strides towards enhancing this life-saving technique. These groundbreaking studies include a trial conducted by Johns Hopkins University, which concluded in October 2021 and focused on evaluating the efficacy of ECMO as a treatment for severe respiratory failure. Another noteworthy trial was led by the University of Pittsburgh Medical Center and finished in September 2021, investigating the use of ECMO to support cardiac arrest patients. These recent advancements underscore the ongoing efforts to refine and optimize ECMO therapies for critically ill individuals relying on this advanced form of life support.